Vaginal Drug Delivery Had A Funding Problem—Merck Changed That

A Goldman Sachs veteran says this platform would have funded faster as a rectal drug. Merck disagreed. Here's what took so long.

Leadership ForbesWomen Vaginal Drug Delivery Had A Funding Problem—Merck Changed That By Geri Stengel , Contributor. Forbes contributors publish independent expert analyses and insights. Geri Stengel writes about the success factors of women entrepreneurs. Follow Author Apr 20, 2026, 07:00am EDT --:-- / --:-- This voice experience is generated by AI. Learn more . This voice experience is generated by AI. Learn more . Callavid, Calla Lily Clinical Care's tampon-shaped vaginal drug delivery device, is designed to hold medication in place during absorption, eliminating the leakage that plagues cu

related reading

• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
• History of Women’s Participation in Clinical Researchorwh.od.nih.gov
• Scaling innovative solutions in women's health with software | Insight Partnersinsightpartners.com
• Liquidity in Drug Discovery – Bharath Ramsundar – Entrepreneur and Scientistrbharath.github.io
• Curious cases of financial engineering in biotechowlposting.com
• Underrepresentation of women in early-stage clinical trialsclinicaltrialsarena.com
• Why Women Hate the Pill | The Walrusthewalrus.ca
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• What We Learned Doing Fast Grants | Futurefuture.a16z.com
• Progress Deferred: mRNA Vaccine Development Lessons | IFPifp.org
• WHAM Launches High-Impact Investment Collaborative - Wham Nowwhamnow.org